reSee.it - Related Video Feed

In this episode of Cold Fusion, Dagogo Altraide discusses how CRISPR technology is restoring sight to individuals with genetic diseases like Leber congenital amaurosis (LCA). CRISPR, a gene-editing tool, allows for precise DNA modifications, enabling researchers to correct genetic defects. Two studies in 2021 showed significant vision improvements in participants after CRISPR treatment, with some regaining color vision. While the results are promising, the treatment is still experimental and not universally effective. Researchers are optimistic about future applications of CRISPR for various diseases, but caution is advised regarding potential unforeseen consequences and ethical concerns surrounding genetic modification.

David Sinclair lays out a personal narrative of why aging is a solvable problem, beginning with a pivotal memory of his Hungarian grandmother and a childhood realization that aging and death aren’t inevitable. He explains his long-term view that aging is a central, modifiable biological process, not a natural fate, and he describes a research program aiming to reset the body's age by reinstating a youthful epigenetic state. The conversation then moves into practical demonstrations from his lab, including work on reversing age in cells, extending lifespan in animals, and the first human trial aimed at restoring function in the eye. Sinclair emphasizes safety and cautious steps in translating animal and primate work to humans, noting that age reversal could first appear as treatments for age-related diseases rather than a blanket rejuvenation, with the eye model serving as a safer starting point. The discussion expands to how aging is driven by epigenetic information and how the body maintains identity through gene expression; aging is framed as an identity crisis in aging cells caused by erasure of epigenetic marks and mislocalization of the proteins that control which genes are active. He argues that turning back this epigenetic clock could simultaneously address multiple diseases, including cancer, neurological disorders, and degenerative conditions, because aging underpins these illnesses. The podcast also tackles lifestyle choices, such as diet, fasting, exercise, sleep, and stress management, highlighting that behavior strongly modulates aging through cellular stress responses and metabolic pathways. They discuss the feasibility and timeline for broad access to such medicines, the regulatory and geopolitical landscape, and the societal implications of longer, healthier lives. The tone remains exploratory and forward-looking, with Sinclair acknowledging remaining uncertainties, the need for rigorous trials, and the ethical and economic questions that will accompany a future in which aging can be slowed, paused, or reversed.

David Sinclair discusses the potential for reversing aging, emphasizing that aging is a loss of information rather than mere physical damage. He believes there is no upper limit to human lifespan, citing examples from other species that live significantly longer. Sinclair's research focuses on epigenetics, revealing that every cell contains a backup copy of information that can be accessed to rejuvenate tissues. He highlights recent breakthroughs in resetting biological age in mice and the promise of similar therapies for humans, particularly in reversing conditions like blindness. Sinclair predicts that within the next two years, human clinical trials for age reversal will begin. He stresses the importance of lifestyle choices in maintaining a youthful biological age and mentions ongoing research to develop affordable age-reversal therapies. Sinclair's work aims to make these advancements accessible to all, not just the wealthy, and he is optimistic about the future of longevity science.

In this episode of the Huberman Lab, Dr. Tony Wyss-Coray discusses research on aging, focusing on how factors in young blood and in blood after exercise can influence aging in the brain and other tissues. The conversation highlights experiments where old animals exposed to young blood showed reactivated brain stem cells, reduced inflammation, and improved memory, suggesting that certain circulating proteins decline with age while others promote regeneration. Wyss-Coray explains how the aging process is not uniform across organs: different tissues age at different rates, and scientists can measure organ-specific aging through proteomic analyses of blood and cerebrospinal fluid. The discussion covers how young-blood factors might act directly on cells, but also how aging involves inflammatory molecules that opposingly impair function. The guests describe efforts to translate these findings to humans, including therapeutic plasma exchange and fractionated blood products, as well as small clinical trials in neurodegenerative diseases. They emphasize that aging research is moving toward identifying multiple factors that act in concert rather than a single magic bullet, with attention to how organ-specific aging can be predicted and potentially reversed. The conversation also addresses the balance between vitality-enhancing interventions (such as exercise, sunlight, and certain hormonal or growth-factor pathways) and longevity, acknowledging the tradeoffs scientists often observe, such as growth hormone–IGF-1–related vitality versus lifespan effects. Throughout, the speakers stress the importance of rigorous, controlled studies and caution against unproven therapies, including out-of-country stem-cell procedures. They also explore how lifestyle factors—sleep, light exposure, social interaction, diet, and physical activity—intersect with circulating factors to shape healthspan. The episode closes with reflections on future directions, including organ- and cell-type aging maps, the potential for personalized interventions guided by proteomic and wearable data, and the prospect of bringing science-backed tools to the public in a careful, clinically validated way.

Dax Shepard hosts David Sinclair, an Australian biologist and professor of genetics known for his research on aging and longevity. Sinclair discusses his background, including his PhD from the University of New South Wales and his work at Harvard Medical School since 1999. He emphasizes the importance of longevity research, distinguishing it from anti-aging, which he associates with snake oil salesmen. Sinclair believes that understanding aging can lead to significant advancements in medicine, arguing that aging should not be accepted as a natural process but rather as a condition that can be treated. Sinclair explains that traditional medicine focuses on diseases rather than the aging process itself, which he sees as a missed opportunity. He discusses the role of the epigenome in aging, suggesting that it deteriorates over time, leading to inefficient gene expression. Sinclair's lab has made breakthroughs in reversing aging in mice, using a combination of embryonic genes to reset cellular age. He mentions the potential for this technology to be applied to humans, with hopes of clinical trials in the near future. The conversation touches on the societal implications of extended lifespans, including ethical dilemmas and the potential for increased suicide rates if people feel trapped in a long life. Sinclair acknowledges the need for discussions about the consequences of longevity research, including economic impacts and the potential for societal changes in perceptions of age and wisdom. Sinclair expresses optimism about the future of aging research, predicting breakthroughs within the next five years that could lead to significant advancements in health and longevity. He emphasizes the importance of public discourse on these topics, advocating for transparency and direct communication between scientists and the public.

The hosts discuss a range of topics, starting with a humorous exchange about their vacation schedules. The main focus shifts to economic updates, particularly inflation, which has eased to 3% in June, the slowest pace in over two years. Friedberg mentions Larry Summers' view that interest rates may need to remain high for longer due to structural changes in the economy, including a decoupling from China and increased global security spending. Chamath agrees, suggesting that the equity market could rise as capital shifts back into growth assets. The conversation also touches on the psychology of consumer spending, emphasizing that while consumers may downgrade their purchases, they remain resilient. Rising credit card debt and increased monthly payments due to higher interest rates are highlighted as potential challenges for consumer spending. The hosts speculate on the implications of recent legal rulings, including a judge's decision favoring Ripple in its case against the SEC, which could impact the broader crypto market. The discussion then transitions to the geopolitical landscape, particularly NATO's expansion with Finland and Sweden joining, and the implications for U.S. defense commitments. The hosts express concerns about the military-industrial complex's influence on NATO's growth and the potential risks of escalating tensions with Russia. Finally, they delve into advancements in biotechnology, specifically the potential for reversing aging through small molecules that target cellular epigenetics, which could lead to significant breakthroughs in health and longevity. The episode concludes with a light-hearted note about personal experiences and camaraderie among the hosts.

Researchers, led by Dr. Sinclair at Harvard, are exploring health regeneration and the aging process. They discovered that aging is linked to the epigenome, which controls DNA expression. Experiments on mice showed that altering epigenetic information can reverse aging effects, with treated mice running significantly longer. The focus is on boosting NAD levels, which decline with age, using compounds like NMN. Additionally, the Yamanaka factors may enable regeneration of damaged cells. While still in research, these findings could improve health and quality of life in aging populations.

In this episode of the Peter Attia Drive, host Peter Attia interviews Matt Kaeberlein, a prominent researcher in the biology of aging from the University of Washington. They discuss Kaeberlein's work with the Dog Aging Project, which uses dogs as a model for understanding aging due to their close relationship with humans and shared environments. This research aims to explore genetic and environmental factors influencing aging and to test interventions that may extend lifespan and healthspan. Kaeberlein shares his background, including his PhD work on sirtuins, which are linked to lifespan extension in various organisms. He emphasizes the unique position of dogs in aging research, as they experience many of the same age-related diseases as humans, such as cancer and kidney disease, but with different prevalence rates. The conversation highlights the potential of rapamycin, a drug known for its effects on mTOR signaling, to improve healthspan and possibly extend lifespan in dogs. The discussion covers the challenges of studying aging in dogs compared to shorter-lived laboratory animals like mice, particularly regarding mortality and the need for proxy measures of health. Kaeberlein describes a 10-week study on rapamycin's effects on heart function in middle-aged dogs, which showed promising results without significant side effects. They also touch on the importance of understanding dosing and timing for rapamycin to maximize benefits while minimizing risks. Kaeberlein expresses optimism about the potential for rapamycin to rejuvenate various organ functions, including immune and cardiac health, and discusses the need for further studies to explore these effects in both dogs and humans. He outlines plans for a larger, five-year study involving hundreds of dogs to assess the long-term impacts of rapamycin on aging and healthspan, emphasizing the significance of such research for public perception and the future of aging studies. The episode concludes with reflections on the broader implications of aging research and the potential for interventions that could improve quality of life for both pets and their owners.

In this episode of "Moonshots," Peter Diamandis interviews Dr. David Sinclair, a leading scientist in longevity and age reversal. They discuss the potential for age reversal technologies that could allow individuals to take a pill for a few weeks and effectively become younger. Sinclair explains that aging is primarily an issue of the epigenome, which can be reset without cloning. He shares insights from his research, including the ability to reverse aging in cells by reprogramming them, which has been demonstrated in mice and monkeys. Sinclair predicts that by 2035, age reversal therapies will be available for humans, with initial trials starting soon. He emphasizes the role of AI in accelerating research, allowing for rapid experimentation that would have taken decades in the past. Sinclair's lab is working on gene therapies that could potentially cure diseases like blindness and even reverse aging in tissues. The conversation touches on the costs of these therapies, with Sinclair aiming to reduce them significantly, potentially to just a few dollars per treatment. They also discuss the concept of "longevity escape velocity," where advancements in science could allow people to extend their lives indefinitely as they age. Sinclair highlights the importance of maintaining health through exercise, diet, and supplements, and shares his personal regimen, which includes various longevity-promoting substances. He stresses that the current medical system often focuses on treating symptoms rather than addressing the underlying causes of aging. The episode concludes with a discussion on the societal implications of increased longevity, including economic impacts and the need for a positive vision of the future. Sinclair believes that as we advance in age reversal technologies, we will need to rethink our approach to aging and health, ensuring that everyone has access to these innovations.

Investment in aging research is surging, promising advancements in chronic disease management. Stem cell research has evolved from embryonic controversies to synthetic biology, particularly with induced pluripotent stem cells (iPSCs), which can be derived from any somatic cell and reprogrammed. This breakthrough allows for standardized cell production, enhancing treatment efficacy. Recent trials have shown iPSCs can regenerate dopamine neurons in Parkinson's patients, indicating significant potential for neurodegenerative diseases. Current therapies include exosomes, which carry signaling molecules to promote healing, and are being explored for conditions like Alzheimer's. The U.S. lags in regulatory frameworks for stem cell therapies compared to countries like Japan, where such treatments are legal and regulated. Chronic diseases, including cancer, are largely lifestyle-related, with a focus on nutrition, exercise, and social connections being vital for health. Emerging therapies like follistatin gene therapy show promise in reducing biological age and enhancing muscle growth without exercise. The future may see organ regeneration through advanced techniques, while lifestyle modifications remain crucial. The conversation emphasizes the need for innovative approaches to health, bridging gaps in conventional medicine and addressing chronic conditions effectively.

In this episode of The Drive, host Peter Attia welcomes back Professor David Sinclair, a prominent researcher in the field of aging and longevity. Sinclair is known for his work on sirtuins and the role of NAD (nicotinamide adenine dinucleotide) in aging. The discussion centers around Sinclair's new book, which explores the information theory of aging, the biological mechanisms behind aging, and potential interventions to extend lifespan. Attia explains his decision to rely on listener support for the podcast instead of advertisements, emphasizing the importance of trust and the desire to provide unbiased information. Sinclair shares insights into his research, particularly the significance of sirtuins, which are proteins that regulate cellular health and longevity. He discusses the discovery of sirtuins in yeast and their connection to dietary restriction and aging. The conversation delves into the concept of the information theory of aging, which posits that aging is a loss of information in the body's cells. Sinclair explains how this theory relates to the maintenance of cellular identity and the role of epigenetic modifications, such as DNA methylation, in aging. He likens the aging process to a loss of cellular identity, where cells revert to a more primitive state. Sinclair introduces the idea of reprogramming cells to restore youthful characteristics, drawing parallels to stem cell technology. He discusses ongoing research that suggests it may be possible to reset the aging clock in cells, potentially leading to significant health improvements. The conversation also touches on the implications of extending human lifespan, including ethical considerations and societal impacts. The discussion shifts to NAD and its precursors, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Sinclair explains how these compounds can boost NAD levels in the body, which is crucial for sirtuin activity and overall cellular function. He highlights the differences between oral and intravenous administration of NAD and the challenges associated with absorption and bioavailability. Attia and Sinclair explore the potential benefits of NAD supplementation, particularly for individuals with metabolic disorders or age-related decline. Sinclair emphasizes the importance of ongoing research to determine the efficacy of NAD boosters in humans and the need for well-designed clinical trials. The episode concludes with Sinclair discussing his artistic endeavors, including the illustrations in his book, and Attia expressing his appreciation for Sinclair's insights and contributions to the field of longevity research. Sinclair's book aims to provide a fresh perspective on aging and the potential for extending healthy lifespan through scientific advancements.

Dr. Rhonda Patrick discusses how biological aging differs from chronological age and outlines lifestyle choices that can influence cellular aging, including the potential for regenerative approaches such as induced pluripotent stem cells and gene therapy. She explains how aging might be slowed or reversed at the organ level, with an emphasis on the brain and heart, and describes how stresses like obesity, inflammation, and poor metabolic health accelerate aging. The conversation covers the rapid trajectory of AI in science, highlighting how artificial intelligence and machine learning could accelerate understanding of aging processes and translate lab findings into human therapies, while also acknowledging that AI can generate errors and requires careful, evidence-based use. The host and guest explore three forward-looking possibilities in biotechnology, including reprogramming aging cells while preserving cell identity, growing organs from a patient’s own cells to avoid immune rejection, and delivering longevity-associated genes through gene therapy or gene editing tools such as CRISPR. They also debate the ethical implications of gene enhancement and the prospect of choosing physical traits in offspring, noting the social and moral questions that would accompany such capabilities. The discussion expands to practical health strategies, with a focus on exercise as a critical determinant of cardiovascular and brain health. They review intensive, evidence-backed exercise regimens that can reverse certain aging markers in middle age, compare high-intensity interval training to steady activity, and emphasize viewing exercise as personal hygiene. Alongside physical activity, they cover dietary approaches, intermittent fasting, and the role of ketones in cognitive endurance, particularly under stress, as well as creatine’s dual impact on muscle performance and brain energy. The guests also touch on the gut–brain axis, describing how gut inflammation, LPS translocation, and microbiome composition influence mood, cognition, and disease risk, while underscoring that diet quality, fiber, and activity are central to a healthier gut. The discussion closes with reflections on happiness, purpose, relationships, and mortality awareness as foundational components of longevity, linking science to everyday life choices including family, spirituality, and mental well-being.

The All-In crew opens with the ongoing clash between politics and monetary policy, noting that Trump fired Fed Governor Lisa Cook and that Cook has sued the White House, with an emergency hearing set for Friday and a potential Supreme Court review. They outline the CHIPS Act angle, where the government would take a 10% stake in Intel in exchange for grants and loans, a deal described as conveying equity rather than a free handout. They highlight the tension around Fed independence and the political optics of such moves. Discussion shifts to the Fed’s role and its independence. The panel debates whether central-bank governors are truly insulated or political appointees, contrasting the 14‑year terms with the reality of appointments by presidents. They dissect what the Fed actually does: lender of last resort, price stability, banking supervision, and payment systems. The group argues that some tasks might be better served by Treasury or free markets, proposing real‑time pricing via blockchain publishing of GDP and employment data to guide rates, reducing reliance on a handful of monthly reads and potentially changing rate setting. More money matters follow: real estate debt pressures surface as large corporate bankruptcies rise in 2025, partly after a long era of near-zero rates that masked vulnerabilities; the conversation notes that CRE debt maturities and refinancing risks threaten balance sheets, with valuations compressing as rates rise. They discuss the timing of rate cuts and dissent within the Fed, acknowledging two dissents for July versus September expectations, and critique the politics of “weaponization” and lawfare, while entertaining the possibility that the Fed’s independence should be revisited in favor of market mechanisms. Biotech and aging research emerge as a science thread. The hosts cover OpenAI’s longevity breakthrough model GPT4B micro, trained on protein sequences and 3D structure data, which generated candidate proteins for OSK/M rejuvenation. They report dramatic results: OSK/M proteins made 50x more effective; by day 7, 30% of cells expressed stem cell markers; by day 12, 85% did. They discuss Yamanaka factors OSK and M and the cancer risk if cells revert too far. They assess the clinical path: a 7–12 year horizon for an initial drug, with trials targeting specific diseases first, and future aging indications. They also touch on broader AI‑driven biotech, model fine‑tuning, and potential mass‑market applications, including a Costa Rica hospitality angle as a speculative aside.

In this episode of the Drive podcast, host Peter Attia interviews Ned David, co-founder and president of Unity Biotechnology, focusing on the science of cellular senescence and its implications for longevity and healthspan. They discuss the concept of senescence, which refers to the state where cells stop dividing due to stress and accumulate with age, contributing to various age-related diseases. Ned explains that aging is not a fixed process but rather a flexible one, influenced by various biochemical systems that can be manipulated. He highlights three principles: aging is malleable, nature has control knobs that can be turned, and these knobs can be targeted for therapeutic interventions. They explore examples from nature, such as the differing lifespans of similar species, to illustrate the potential for extending healthspan through scientific advancements. Ned shares his background as a serial entrepreneur in biotechnology, detailing his experiences in developing FDA-approved compounds and how these experiences shaped his approach to Unity. He emphasizes the importance of understanding the biological mechanisms of aging, particularly cellular senescence, and how it can be targeted to improve health outcomes. The conversation shifts to Unity's research on senolytic therapies, which aim to eliminate senescent cells to alleviate age-related conditions like osteoarthritis. Ned describes their findings from animal studies showing that removing senescent cells can lead to significant improvements in health and lifespan. They discuss the implications of these findings for human health, particularly in treating osteoarthritis, a condition that affects many older adults. Ned outlines the results of Unity's phase one clinical trial, which demonstrated that a single injection of their senolytic drug significantly reduced pain in patients with osteoarthritis. He notes that the drug targets senescent cells by inhibiting specific pathways, leading to their selective death without harming healthy cells. The discussion touches on the potential for this approach to extend beyond osteoarthritis to other age-related diseases, including Alzheimer's and cardiovascular diseases. Throughout the episode, Ned emphasizes the importance of collaboration and learning from others in the field, as well as the need for a clear understanding of the risks involved in drug development. He encourages aspiring scientists and entrepreneurs to pursue their passions while remaining open to the possibilities of both academic and entrepreneurial pathways. In conclusion, the conversation highlights the exciting potential of targeting cellular senescence as a strategy for improving healthspan and longevity, with Unity at the forefront of this innovative research.

In this episode of the Joe Rogan Experience, Dr. Rhonda Patrick discusses various topics related to health, nutrition, and the biological mechanisms behind stress and anxiety. She explains the role of dynorphin and endorphins in managing anxiety and how the feeling of anxiety before performing can lead to a greater endorphin rush afterward. They explore the concept of hormesis, where mild stressors, such as exercise or certain foods, can have beneficial effects on the body by activating stress response mechanisms. Rogan and Patrick delve into the importance of exercise for mental health, neurogenesis, and the production of brain-derived neurotrophic factor (BDNF), which supports the growth of new neurons. They discuss the significance of serotonin in memory and mood regulation, and how its levels can be influenced by various factors, including diet and exercise. The conversation shifts to the role of vitamin D in health, with Patrick emphasizing that many people are deficient in it and that it plays a crucial role in various bodily functions, including immune response and mental health. She highlights the need for adequate vitamin D levels for optimal health and discusses the potential implications of low levels on conditions like autism. They also touch on the importance of antioxidants and the misconceptions surrounding their use. Patrick critiques the oversimplification of the effects of vitamins and antioxidants, particularly in the context of cancer prevention and treatment. She argues that context is essential when evaluating the benefits of supplements, as the effects can vary significantly based on individual health status and existing deficiencies. Patrick mentions the potential of stem cell research and the exciting developments in regenerative medicine, including the possibility of reprogramming cells to reverse aging effects. They discuss the implications of recent studies showing that young blood can rejuvenate old mice, enhancing their physical and cognitive abilities, and the potential for similar applications in humans. The episode concludes with a discussion on the challenges of obtaining funding for innovative research in nutrition and aging, emphasizing the need for continued exploration in these fields. Patrick promotes her app, FoundMyFitness, which provides resources on health and nutrition, and encourages listeners to engage with her work through her website and social media.